MX2015005949A - Nucleosidos que contienen aza-azucar antiviral. - Google Patents
Nucleosidos que contienen aza-azucar antiviral.Info
- Publication number
- MX2015005949A MX2015005949A MX2015005949A MX2015005949A MX2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A MX 2015005949 A MX2015005949 A MX 2015005949A
- Authority
- MX
- Mexico
- Prior art keywords
- azasugar
- compounds
- viral
- pharmaceutically acceptable
- antiviral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos que comprenden un aza-azúcar unido a una base heterocíclica, que incluyen sales de los mismos farmacéuticamente aceptables, adecuados para uso en la inhibición de la actividad de polimerasa del ARN o replicación viral, y tratar infecciones virales. Los compuestos son caracterizados, en parte, por farmacocinéticas favorables para el ingrediente farmacéutico activo, particularmente en conjunto con administración entérica, que incluye, en particular, administración oral. También se describen composiciones farmacéuticas que comprenden uno o más compuestos mencionados anteriormente, o sales de los mismos farmacéuticamente aceptables, así como también métodos para preparar los mismos. También se proporcionan métodos para inhibir la actividad de la polimerasa de ARN viral, replicación viral, y tratar infecciones virales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261727468P | 2012-11-16 | 2012-11-16 | |
PCT/US2013/070537 WO2014078778A2 (en) | 2012-11-16 | 2013-11-18 | Antiviral azasugar-containing nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015005949A true MX2015005949A (es) | 2015-09-08 |
Family
ID=50731836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005949A MX2015005949A (es) | 2012-11-16 | 2013-11-18 | Nucleosidos que contienen aza-azucar antiviral. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20150291596A1 (es) |
EP (2) | EP3251674A3 (es) |
JP (1) | JP2016504284A (es) |
AU (1) | AU2013344422A1 (es) |
CA (1) | CA2890905A1 (es) |
HK (1) | HK1212235A1 (es) |
IL (1) | IL238785A0 (es) |
MX (1) | MX2015005949A (es) |
WO (1) | WO2014078778A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
PL2595980T3 (pl) | 2010-07-22 | 2015-03-31 | Gilead Sciences Inc | Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
ES2918585T3 (es) | 2015-09-16 | 2022-07-19 | Gilead Sciences Inc | Métodos para el tratamiento de infecciones por el virus Arenaviridae |
JP6948322B2 (ja) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン |
PE20190175A1 (es) | 2016-03-28 | 2019-02-01 | Incyte Corp | Compuestos de pirrolotriazina como inhibidores de tam |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
EP3595672B1 (en) | 2017-03-14 | 2023-09-06 | Gilead Sciences, Inc. | Compounds for use in methods of treating feline coronavirus infections |
CN106834546A (zh) * | 2017-03-20 | 2017-06-13 | 杭州迪安医学检验中心有限公司 | 一种基于熔解曲线法单管同时检测多种呼吸道病毒的引物及其应用 |
ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
EP3651734A1 (en) | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
CN109053788A (zh) * | 2018-09-20 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种吡唑类化合物的制备方法 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ, インコーポレイテッド | SARS CoV-2感染を治療するための方法 |
TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
EP4157272A1 (en) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Remdesivir treatment methods |
TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
CN111704619B (zh) * | 2020-07-30 | 2021-10-19 | 四川大学 | 一种Forodesine的制备方法 |
TW202228722A (zh) | 2020-08-27 | 2022-08-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
CN114588159A (zh) * | 2020-12-07 | 2022-06-07 | 成都傲科新技术有限责任公司 | 一种治疗猫冠状病毒感染的化合物及其应用 |
EP4361148A1 (en) * | 2021-06-25 | 2024-05-01 | Albius Sciences Alpha Private Limited | Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease |
KR20240050362A (ko) | 2021-08-20 | 2024-04-18 | 시오노기 앤드 컴파니, 리미티드 | 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그 |
CN113666941B (zh) * | 2021-09-01 | 2023-03-10 | 浙江珲达生物科技有限公司 | 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法 |
EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
EP0630904A4 (en) * | 1992-08-26 | 1995-01-04 | Japan Tobacco Inc. | Novel nicotine derivative. |
US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
AU2003233667A1 (en) * | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
US7745417B2 (en) * | 2002-07-17 | 2010-06-29 | Riken | Nucleosides or nucleotides having novel unnatural bases and use thereof |
EP2189466A3 (en) | 2002-12-04 | 2010-09-08 | Mitsubishi Gas Chemical Company, Inc. | Method of fluorination by microwaves |
US6780993B1 (en) * | 2003-02-19 | 2004-08-24 | Biocryst Pharmaceuticals, Inc. | Preparation of deazaguanine analog |
TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
US7560434B2 (en) * | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
EP1814561A4 (en) * | 2004-10-29 | 2012-12-19 | Biocryst Pharm Inc | THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES |
PT1891038E (pt) * | 2005-05-13 | 2008-12-02 | Lilly Co Eli | N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio |
CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
AU2006318275A1 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Calcilytic compounds |
MX2008007103A (es) | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
WO2007109459A2 (en) | 2006-03-21 | 2007-09-27 | Janssen Pharmaceutica, Nv | Pyridines and pyridine n-oxides as modulators of thrombin |
WO2007125061A1 (en) | 2006-04-27 | 2007-11-08 | Glaxo Group Limited | Spirocompounds useful as modulators for dopamine d3 receptors |
PT2114980E (pt) * | 2007-01-12 | 2012-09-25 | Biocryst Pharm Inc | Análogos de nucleósidos anti-virais |
PL2155758T3 (pl) * | 2007-05-10 | 2013-06-28 | Biocryst Pharm Inc | Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka |
EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
EP2348854A4 (en) * | 2008-09-22 | 2012-03-14 | Einstein Coll Med | METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
RS54072B1 (en) * | 2010-10-15 | 2015-10-30 | Biocryst Pharmaceuticals Inc. | COMPOSITIONS FOR USE IN THE TREATMENT OF Viral INFECTIONS |
AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2013
- 2013-11-18 CA CA2890905A patent/CA2890905A1/en not_active Abandoned
- 2013-11-18 EP EP17162146.9A patent/EP3251674A3/en not_active Withdrawn
- 2013-11-18 JP JP2015542870A patent/JP2016504284A/ja active Pending
- 2013-11-18 MX MX2015005949A patent/MX2015005949A/es unknown
- 2013-11-18 US US14/441,762 patent/US20150291596A1/en not_active Abandoned
- 2013-11-18 WO PCT/US2013/070537 patent/WO2014078778A2/en active Application Filing
- 2013-11-18 AU AU2013344422A patent/AU2013344422A1/en not_active Abandoned
- 2013-11-18 EP EP13855441.5A patent/EP2919785A4/en not_active Withdrawn
-
2015
- 2015-05-13 IL IL238785A patent/IL238785A0/en unknown
-
2016
- 2016-01-12 HK HK16100301.6A patent/HK1212235A1/xx unknown
-
2017
- 2017-03-31 US US15/475,507 patent/US20170267681A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170267681A1 (en) | 2017-09-21 |
WO2014078778A2 (en) | 2014-05-22 |
EP3251674A2 (en) | 2017-12-06 |
EP3251674A3 (en) | 2018-02-21 |
CA2890905A1 (en) | 2014-05-22 |
IL238785A0 (en) | 2015-06-30 |
WO2014078778A3 (en) | 2014-10-09 |
US20150291596A1 (en) | 2015-10-15 |
HK1212235A1 (en) | 2016-06-10 |
EP2919785A2 (en) | 2015-09-23 |
AU2013344422A1 (en) | 2015-07-02 |
JP2016504284A (ja) | 2016-02-12 |
EP2919785A4 (en) | 2016-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
MX2013008359A (es) | Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana. | |
TN2013000421A1 (en) | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
GEP201706698B (en) | Inhibitors of influenza viruses replication | |
WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
PH12015500749A1 (en) | 2`chloro nucleoside analogs for hcv infection | |
NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
WO2010084115A3 (en) | Antiviral agents | |
BR112014027117A2 (pt) | derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson | |
WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
MX363270B (es) | Composiciones y metodos para inhibir la polimerasa viral. | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
EP2583962A4 (en) | NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT | |
WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug | |
EP2842938A4 (en) | NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | |
MX350516B (es) | Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2. | |
WO2012169863A3 (en) | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | |
WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии |